ISTN receives NIH Nanotechnology Grant for the development of an Immobilized Enzyme Technology
The initial studies will be aimed at producing chiral specific drug intermediates targeted toward the pharmaceutical industry. Clinical studies have clearly demonstrated the superior value of chiral drugs. A majority of clinical results have shown that only one enantiomer of a drug provides the desired activity while the counterparts are inactive or, even toxic. Among the world's current top ten selling drugs (such as Lipitor, Zocor, etc.), nine active ingredients are chiral. At present, over half of the chiral products are made by traditional methods (pool and separation), one third are produced by chemocatalysis, and only about 15% are derived from biocatalysis. However, the trend is changing in favor of biocatalysis due to the tremendous progresses in biomedicines, including high throughput screening, modern molecular biology techniques such as directed evolution as well as surges in the fields of genomics and bioinformatics.
In addition to the pharmaceutical industry ISTN has identified a number of other large markets that would benefit from development of this novel chemical synthesis method. The nearly $50 billion LCD market is expected to be one of the largest consumers of fine chemicals in the years ahead and a technology to more efficiently produce many of these compounds could see a large commercial reward. In addition, enzymatic synthesis and separation is expected to play a large role in the food and beverage industries as traditional production methods are replaced.
Topics
Organizations
Other news from the department research and development
Get the analytics and lab tech industry in your inbox
From now on, don't miss a thing: Our newsletter for analytics and lab technology brings you up to date every Tuesday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.